Clinical Trial Update: Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ADAPTAVIR evaluating safety and potential to eliminate treatment-resistant HIV in peripheral blood mononuclear cells; status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ADAPTAVIR

Snippet

Sponsor: Rapid Laboratories Inc. | Conditions: HIV Infections | Phase 2 | Status: UNKNOWN